CSSSI

AcronymDefinition
CSSSIComplicated Skin and Skin Structure Infections
References in periodicals archive ?
In June 2016, several CSSSI librarians created a 1-hour session that redefined our introductory Google workshop.
A total of 389 cSSSI patients were included in the study, with 257 receiving daptomycin and 132 receiving standard-of-care (SOC) treatment (mostly vancomycin or clindamycin).
"When patients with cSSSI or HABP/VABP present with concurrent bacteremia, their treatment becomes more difficult for healthcare practitioners.
This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
The proposed cSSSI dose is 600 mg administered intravenously every 12 hours for 5-14 days, with a lower dose for people with moderate to severe renal impairment.
A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).
The agency asked the company to perform an additional clinical study to show efficacy and safety of the drug, oritavancin, for treating complicated skin and skin structure infections (cSSSI), Targanta said, citing a response letter from the FDA.
Telavancin, which is a lipoglycopeptide injectable antibiotic, is currently in phase 3 studies for the treatment of complicated skin and skin structure infections (cSSSI) and Hospital-acquired pneumonia (HAP) conducted in the US.
aureus when alternative treatments are unsuitable, and also of adults with complicated skin and skin structure infections (cSSSI) resulting from susceptible isolates of gram-positive bacteria which includes S.
Table 3: IPEX Markets According to Various Zone Configurations (2004-2007)(a b c) Four-market N NCn N N N N Markets CnCsS Sa CnSa Cn CnCs CnSaCs Sa CsS CsS Sa Sa S Si Si Si CsSSi SSi Si No.
(3) Tigecycline is the first glycylcycline class of antibiotic which has bacteriostatic activity against MRSA, has been approved by US FDA for the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections.
[USPRwire, Tue Jul 28 2015] Global Markets Direct's, 'Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015', provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI)'s therapeutic pipeline.